Yahoo
NYSE - Nasdaq Real Time Price USD

Stryker Corporation (SYK)

296.57 -15.18 (-4.87%)
As of 12:44:14 PM EDT. Market Open.
Trade Stryker on Coinbase
SYK Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for SYK

What's happening with SYK?

21m ago
Powered by Yahoo Scout

Stryker’s third-quarter 2026 results showed solid organic growth, but weaker hip and knee procedures caused revenue and adjusted earnings to miss estimates. The company reduced its full-year outlook, while margin expansion, share repurchases, new robotics partnerships, and leadership succession provided offsets.

Powered by Yahoo Scout
  • Previous Close 311.75
  • Open 287.97
  • Bid 296.55 x 4000
  • Ask 296.80 x 12000
  • Day's Range 282.18 - 299.17
  • 52 Week Range 267.00 - 389.33
  • Volume 3,568,080
  • Avg. Volume 2,656,520
  • Market Cap (intraday) 113.756B
  • Beta (5Y Monthly) 0.78
  • PE Ratio (TTM) 30.74
  • EPS (TTM) 9.65
  • Earnings Date (est.) Jan 28, 2027
  • Forward Dividend & Yield 3.52 (1.13%)
  • 1y Target Est 362.62
  • Morningstar Rating Rating available with Stock Picks access

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

www.stryker.com

56,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SYK
14.88%
S&P 500 (^GSPC)
10.80%

1-Year Return

SYK
18.72%
S&P 500 (^GSPC)
11.17%

3-Year Return

SYK
16.36%
S&P 500 (^GSPC)
82.02%

5-Year Return

SYK
17.52%
S&P 500 (^GSPC)
64.69%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 6.52B
Earnings 753M
Profit Margin 11.55%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
2B
4B
6B
12.0%
14.0%
16.0%
18.0%

Analyst Insights

View More

Analyst Price Targets

298.00
362.62 Average
296.57 Current
465.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/30/2026
Analyst Barclays
Rating Action Maintains
Rating Overweight
Price Action Lowers
Price Target 375 -> 365

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.43%

  • Return on Assets (ttm)

    8.16%

  • Return on Equity (ttm)

    16.51%

  • Revenue (ttm)

    25.84B

  • Net Income Avi to Common (ttm)

    3.73B

  • Diluted EPS (ttm)

    9.65

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.48B

  • Total Debt/Equity (mrq)

    64.39%

  • Levered Free Cash Flow (ttm)

    4.11B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: